[go: up one dir, main page]

BRPI0408698A - alimento para melhorar as condições clìnicas capazes de diminuir a concentração de compostos contendo nitrogênio de peso molecular baixo no sangue - Google Patents

alimento para melhorar as condições clìnicas capazes de diminuir a concentração de compostos contendo nitrogênio de peso molecular baixo no sangue

Info

Publication number
BRPI0408698A
BRPI0408698A BRPI0408698-8A BRPI0408698A BRPI0408698A BR PI0408698 A BRPI0408698 A BR PI0408698A BR PI0408698 A BRPI0408698 A BR PI0408698A BR PI0408698 A BRPI0408698 A BR PI0408698A
Authority
BR
Brazil
Prior art keywords
food
clinical conditions
molecular weight
blood
improve clinical
Prior art date
Application number
BRPI0408698-8A
Other languages
English (en)
Inventor
Yasumi Yugari
Takaaki Kobayashi
Shu Furuya
Original Assignee
Cheiron Japan Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cheiron Japan Co filed Critical Cheiron Japan Co
Publication of BRPI0408698A publication Critical patent/BRPI0408698A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"ALIMENTO PARA MELHORAR AS CONDIçõES CLìNICAS CAPAZES DE DIMINUIR A CONCENTRAçãO DE COMPOSTOS CONTENDO NITROGêNIO DE PESO MOLECULAR BAIXO NO SANGUE". é pretendido fornecer um alimento novo para melhorar as condições clínicas pelas quais a mudança para hemodiálise no tratamento de insuficiência renal pode ser impedida ou retardada, a freqüência de hemodiálise pode ser diminuída ou o começo de hiperamonemia na insuficiência hepática pode ser impedida ou aliviada. Isto é, um alimento para melhorar as condições clínicas, que aponta na obtenção do objetivo anterior, caracterizado por conter polissacarídeos dificilmente digestíveis como os componentes principais juntamente com uma quantidade restrita de componentes protéicos. Consumindo este alimento para melhorar as condições clínicas, proteínas microbianas são sintetizadas empregando-se a energia gerada pelo metabolismo dos polissacarídeos dificilmente digestíveis e uréia e amónia secretadas nos intestinos como uma fonte de N e dessa maneira as células microbianas proliferadas são descarregadas nas fezes. De acordo com este mecanismo, compostos contendo nitrogênio de baixo peso molecular no sangue podem ser reduzidos e, como um resultado, insuficiência renal e insuficiência hepática podem ser melhoradas.
BRPI0408698-8A 2003-03-26 2004-03-26 alimento para melhorar as condições clìnicas capazes de diminuir a concentração de compostos contendo nitrogênio de peso molecular baixo no sangue BRPI0408698A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003086141 2003-03-26
PCT/JP2004/004319 WO2004084919A1 (ja) 2003-03-26 2004-03-26 血中低分子量含窒素化合物の濃度を低減させる病態改善用食品

Publications (1)

Publication Number Publication Date
BRPI0408698A true BRPI0408698A (pt) 2006-03-28

Family

ID=33095050

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408698-8A BRPI0408698A (pt) 2003-03-26 2004-03-26 alimento para melhorar as condições clìnicas capazes de diminuir a concentração de compostos contendo nitrogênio de peso molecular baixo no sangue

Country Status (8)

Country Link
US (1) US20060210606A1 (pt)
EP (1) EP1616570A4 (pt)
JP (1) JPWO2004084919A1 (pt)
KR (1) KR100787554B1 (pt)
CN (1) CN100372541C (pt)
BR (1) BRPI0408698A (pt)
CA (1) CA2519761A1 (pt)
WO (1) WO2004084919A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100679750B1 (ko) * 2005-09-14 2007-02-06 김진만 인체체취저감용 보조식품조성물
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8993039B2 (en) 2006-01-25 2015-03-31 Tate & Lyle Ingredients Americas Llc Fiber-containing carbohydrate composition
US8057840B2 (en) * 2006-01-25 2011-11-15 Tate & Lyle Ingredients Americas Llc Food products comprising a slowly digestible or digestion resistant carbohydrate composition
KR101015115B1 (ko) * 2006-07-28 2011-02-16 대상 주식회사 키토산과 알긴산을 포함하는 기능성 당면
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US20120232166A1 (en) * 2009-10-12 2012-09-13 Finley John W Masking Bitter Flavors
WO2021043382A1 (en) * 2019-09-05 2021-03-11 Hesen Sherif Salah Abdulaziz Novel biological enteric dialysis method for ckd and esrd
US11540549B2 (en) 2019-11-28 2023-01-03 Tate & Lyle Solutions Usa Llc High-fiber, low-sugar soluble dietary fibers, products including them and methods for using them

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS574922A (en) * 1980-06-12 1982-01-11 Yakult Honsha Co Ltd Agent for lowering ammonia in blood
EP0276273A1 (en) * 1986-08-02 1988-08-03 FISONS plc Use of certain polysaccharides for the treatment of hepatic or renal failure
JPH07121867B2 (ja) * 1986-11-27 1995-12-25 日本食品化工株式会社 肝機能活性化剤
JPH0622725B2 (ja) 1987-01-12 1994-03-30 株式会社日立製作所 圧延機の制御方法
WO1988008257A1 (fr) * 1987-04-25 1988-11-03 Terumo Kabushiki Kaisha Aliment facilitant l'activite intestinale
JP2779963B2 (ja) * 1989-02-09 1998-07-23 株式会社林原生物化学研究所 ビフィズス菌増殖促進剤
US5200218A (en) * 1989-11-08 1993-04-06 Lasater Priscilla D Composition for dog food
ATE120930T1 (de) * 1990-10-24 1995-04-15 Sandoz Nutrition Ltd Vollwertnahrung aus hydrolysierten löslichen faserstoffen.
JP2978332B2 (ja) * 1992-05-11 1999-11-15 日本化薬株式会社 腸内代謝改善食品および腸内代謝改善剤
JP3602551B2 (ja) * 1993-03-02 2004-12-15 太陽化学株式会社 肝機能障害改善及び予防組成物
JPH10194975A (ja) * 1997-01-10 1998-07-28 Morinaga Milk Ind Co Ltd 肝疾患治療剤
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
JP2000169376A (ja) * 1998-12-10 2000-06-20 Suntory Ltd 高アンモニア血症治療剤
US6207638B1 (en) * 2000-02-23 2001-03-27 Pacifichealth Laboratories, Inc. Nutritional intervention composition for enhancing and extending satiety
JP2002281921A (ja) * 2001-03-28 2002-10-02 Yaizu Suisankagaku Industry Co Ltd 低蛋白澱粉食品

Also Published As

Publication number Publication date
EP1616570A4 (en) 2009-08-12
CN100372541C (zh) 2008-03-05
CA2519761A1 (en) 2004-10-07
KR100787554B1 (ko) 2007-12-21
WO2004084919A1 (ja) 2004-10-07
EP1616570A1 (en) 2006-01-18
US20060210606A1 (en) 2006-09-21
CN1764463A (zh) 2006-04-26
JPWO2004084919A1 (ja) 2006-06-29
KR20060024766A (ko) 2006-03-17
HK1091129A1 (en) 2007-01-12

Similar Documents

Publication Publication Date Title
Cronan et al. Function, attachment and synthesis of lipoic acid in Escherichia coli
Nimni et al. Are we getting enough sulfur in our diet?
Roffi et al. Does platelet‐rich plasma freeze‐thawing influence growth factor release and their effects on chondrocytes and synoviocytes?
Lu et al. Role of abnormal methionine metabolism in alcoholic liver injury
BRPI0408698A (pt) alimento para melhorar as condições clìnicas capazes de diminuir a concentração de compostos contendo nitrogênio de peso molecular baixo no sangue
Bulstrode et al. 5-fluorouracil selectively inhibits collagen synthesis
BRPI0910821A8 (pt) Método para modificar uma proteína, alimento, preparação de enzima para modificar uma proteína, e, método para estabelecer uma relação ótima de proteína glutaminase para transglutaminase
EA200601121A1 (ru) Мутеины фактора роста фибробластов 21
EA200702487A1 (ru) Пегилированные соединения glp-1
BRPI0907502A2 (pt) pelo menos um entidade química, composição, e, métodos para tratar um paciente tendo uma condição, para aumentar a função ou atividade do músculo esquelético, para aumentar a eficiência do músculo esquelético, parab aumentar o tempo da fadiga de fibra muscular esquelética rápida, para sensibilizar uma fibra muscular esquelética rápida para produzir força em resposta a baixas concentreações de íons cálcio e para aumentar o tempo de fadiga muscular esquelética
NO20064489L (no) Sulfaterte oligosakkarid derivater
Turan et al. Selenium combined with vitamin E and vitamin C restores structural alterations of bones in heparin-induced osteoporosis
ES2196053T3 (es) Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.
WO2005113016A3 (en) Modulation of glucose-6-phosphatase translocase expression
Hirawa et al. Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event
Chiol├® ro et al. Nutritional support during renal replacement therapy
Pradhan et al. Successful treatment of ascites of hepatic origin in dog
Wong et al. The anti-obesogenic and anti-diabetic properties of marine collagen peptides
Gong et al. Tamoxifen prevents D-galactosamine/lipopolysaccharide-induced murine acute hepatic failure through inhibition of oxidative stress and Mmd-2 upregulation
Zhang et al. Anti-aging therapeutics for the musculoskeletal and cardiovascular systems: The role of regular exercise
Luo et al. Protective effect of adropin against high fat diet-induced obese diabetic wistar rats via nuclear factor erythroid 2-related factor 2 pathway.
Tingbø et al. Type of carbohydrate in feed affects the expression of small leucine-rich proteoglycans (SLRPs), glycosaminoglycans (GAGs) and interleukins in skeletal muscle of Atlantic cod (Gadus morhua L.)
Okun et al. S-Acetylglutathione normalizes intracellular glutathione content in cultured fibroblasts from patients with glutathione synthetase deficiency
Ahn et al. The role of noble bumblebee (Bombus terrestris) queen glycosaminoglycan in aged rat and gene expression profile based on DNA microarray
Pawłowska et al. Effect of alpha-1 antitrypsin and irisin on post-exercise inflammatory response: a narrative review

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/715 (2006.01), A23L 33/21 (2016.01), A61P

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.